Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus XELOX as neoadjuvant therapy for G/GEJ adenocarcinoma
NCT05507658Phase 2Completed
- Sponsor
- Xijing Hospital
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Xijing Hospital. Started Jul 2022; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05507658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507658.